Source: Serefko, A.; Jach, M.E.; Pietraszuk, M.; Swiader, M.; Swiader, K.; Szopa, A. et al. (2024). Omega-3 Polyunsaturated Fatty Acids in Depression. International Journal of Molecular Sciences, 25(16), 8675. Original link: click here
This article belongs to the Special Issue The Potential Roles of Natural Active Products in Neurological Disorders
Understanding Depression and Its Diagnostic Criteria
Major depressive disorder (MDD) affects an estimated 300 million individuals worldwide. It is a multifactorial illness with contributions from genetic, biological, medical, and psychosocial influences. According to the DSM-5-TR, diagnosis requires at least five of the following symptoms over a two-week period:
- Depressed mood
- Loss of interest or pleasure
- Significant weight changes
- Insomnia or hypersomnia
- Psychomotor agitation or retardation
- Fatigue
- Feelings of worthlessness or excessive guilt
- Impaired cognition or indecisiveness
- Suicidal ideation
One of the symptoms must be either a depressed mood or diminished interest. The symptoms must also cause significant functional impairment and not be explained by another medical condition.
Omega-3 Fatty Acids: A Promising Adjunct in Depression Management
Omega-3 polyunsaturated fatty acids (PUFAs)—particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—cannot be synthesized by the human body and must be obtained via diet or supplements. Found primarily in marine sources, they are known for:
- Anti-inflammatory effects
- Neuroprotection
- Membrane stabilization
Mechanisms of Action
Omega-3s modulate several pathways implicated in depression:
- Neuroinflammation: Suppress proinflammatory cytokines (IL-6, TNF-α)
- Neuroplasticity: Enhance brain-derived neurotrophic factor (BDNF)
- Neurotransmitters: Improve signaling in systems like serotonin and dopamine
- Oxidative stress: Reduce damage associated with depression
These actions align with the HPA axis dysregulation and neuroinflammatory models of depression.
Clinical Evidence: Mixed but Promising
Observational data consistently show a correlation between low omega-3 levels and increased depression risk. However, clinical trials show varied results based on several variables:
- EPA: DHA Ratio: Higher EPA content (>60%) is more effective
- Dosage: 1–2 grams per day of EPA+DHA is optimal
- Population Variance: Women and those with high inflammation markers benefit more
- Formulation: Bioavailability and oxidation level affect outcomes
Importantly, omega-3s are well-tolerated with a strong safety profile, making them suitable for children, the elderly, and pregnant women.
MVS Pharma GmbH – Scientific Application of Research Findings in Product Development
At MVS Pharma GmbH, our scientific team actively evaluates leading research on omega-3 fatty acids to inform our product development. The recent review by Serefko et al. (2024) was particularly relevant as it thoroughly investigates the physiological mechanisms and clinical implications of omega-3 fatty acids, aligning with our core development principles focused on bioavailability, oxidation protection, and pollutant removal.
-
Translating Mechanistic Insights into Formulation Strategies
Neuroinflammation and Neurotransmitter Support
We recognize the importance of EPA and DHA in modulating key neuroinflammatory pathways and supporting neurotransmitter function, as discussed in the article. To support these effects, MVS capsules target inflammation and enhance efficacy in mood-related disorders.
Bioavailability Focus
The report underscores the limited conversion efficiency of ALA to EPA/DHA and highlights the superior therapeutic effects of direct EPA/DHA supplementation. At MVS Pharma, we optimize bioavailability by using re-esterified triglyceride (rTG) forms, which are scientifically proven to provide superior absorption compared to ethyl esters or natural triglyceride oils.
This choice was validated through literature and independent laboratory testing with our production partners. Results consistently showed elevated plasma levels of EPA and DHA post-ingestion compared to standard formulations.
-
Oxidation Stability as a Critical Quality Parameter
Oxidation significantly affects the efficacy and safety of omega-3 supplements. The reviewed article links oxidative stress to depressive symptoms, thus underlining the need for oxidation protection.
We take oxidation extremely seriously:
- Our fish oil is processed under a nitrogen atmosphere to prevent peroxide formation.
- We include IP-certified tocopherols as an antioxidant.
- All batches are rigorously tested for peroxide value (PV) and anisidine value (AV), adhering to stricter-than-standard limits (PV < 5 meq O2/kg, AV < 10).
- Peroxide value – 0.1 meq/kg
- Anisidine value – 4
This ensures that MVS Omega 3 capsules remain potent and safe throughout their shelf life.
-
Removal of Pollutants and Heavy Metals
Contaminants like dioxins, PCBs, and heavy metals (e.g., mercury, cadmium) are a growing concern in marine-sourced products. Though the reviewed article focuses primarily on mental health, the underlying assumption of safety in fish oil supplementation is dependent on effective purification.
Our partners employ a state-of-the-art purification system, including molecular distillation and active carbon filtration, to ensure compliance with:
- EU Regulation (EC) No 1881/2006 for contaminants
- GOED (Global Organization for EPA and DHA Omega-3s) standards
Each production batch is accompanied by a certificate of analysis (CoA), confirming non-detectable levels of heavy metals and below-threshold dioxins and PCBs.
-
Clinical Implications for Product Positioning
The variability in clinical outcomes described in the review inspired us to develop targeted usage recommendations for MVS Omega 3 capsules:
- Dosage: Our recommended dose of 2 capsules/day delivers 1.6 g of total EPA+DHA, with approx. 1 g EPA—based on the most effective range cited in meta-analyses.
- Adjunctive therapy: Based on studies highlighting omega-3s’ benefit in combination with SSRIs and in inflammatory depression, we position our product as a supportive supplement for individuals under mental strain or diagnosed with depressive symptoms.
- Inflammation marker reference: In the future, we plan to explore providing inflammation status markers (e.g., CRP testing) to guide more personalized usage.
-
Literature-Based Validation Process
Our development pipeline included:
- Evaluation of over 30 meta-analyses and clinical trials between 2018 and 2024.
- Independent third-party testing for bioavailability and oxidative stability.
- Regular expert exchange with our production and scientific partners, including analysis of raw material sourcing and encapsulation quality.
We also closely aligned our formulation with the Guu et al. (2019) guideline recommendations for omega-3 use in major depressive disorder, supporting its use as an adjunctive therapy with a minimum of 1 g/day EPA for at least 8 weeks.
Conclusion
Omega-3 fatty acids—especially EPA—hold significant potential as a complementary strategy in depression treatment. The research by Serefko et al. (2024) supports this role, particularly when products are formulated for:
- High bioavailability
- Low oxidation
- Verified purity
The systematic work “Omega-3 Polyunsaturated Fatty Acids in Depression” reinforces the scientific basis for our approach at MVS Pharma GmbH. The key factors discussed—bioavailability, oxidative stability, and contaminant control—directly reflect our formulation of Omega 3. By addressing these critical quality points, we ensure that our product delivers clinically relevant doses of EPA and DHA in a form that is safe, stable, and effective. Ongoing research and collaboration continue to enhance the evidence base, guiding both our product development and consumer education.
FAQ’s section for the Omega-3 and depression topic:
1. What is the link between omega-3 and depression?
Omega-3 fatty acids, especially EPA and DHA, may help reduce depression symptoms by lowering inflammation, supporting neurotransmitter function, and improving brain plasticity.
2. How much omega-3 should I take for depression?
Clinical studies suggest that 1–2 grams per day of EPA+DHA, particularly with an EPA ratio of at least 60%, may be effective for improving mood.
3. Is omega-3 safe for treating depression?
Yes, omega-3s have a strong safety profile and are generally well-tolerated, including by children, the elderly, and pregnant women.
4. Can omega-3 supplements replace antidepressants?
No, but they may serve as a helpful adjunct. Some studies show improved outcomes when omega-3s are combined with antidepressant medications.
5. What makes a high-quality omega-3 supplement for mental health?
Look for products with high EPA content, good bioavailability (like re-esterified triglycerides), low oxidation values, and verified purity from heavy metals and pollutants.
References
- Serefko, A. et al. (2024). Omega-3 Polyunsaturated Fatty Acids in Depression. Int. J. Mol. Sci., 25(16), 8675. https://doi.org/10.3390/ijms25168675
- Guu, T. et al. (2019). Practice Guidelines for Omega-3s in Major Depressive Disorder. Psychother Psychosom, 88(5), 263–273.
- Bayes, J. et al. (2021). Systematic Review and Meta-Analysis. Mol Psychiatry, 26(1), 118–124.
- Kelaiditis, K. et al. (2023). Dose-Response Meta-Analysis of EPA in Depression. J Affect Disord, 330, 321–334.
